Sanofi has announced it will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Centre of Excellence.
The Centre will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated research and development (R&D), digital, and chemistry, manufacturing and controls (CMC) teams across sites in the US and France.
The Centre of Excellence will enable acceleration of the vaccines mRNA portfolio developed through the Translate Bio collaboration established in 2018 and expanded in 2020 and will focus on innovating mRNA vaccines beyond the COVID-19 pandemic to routine use in diseases with high unmet need.
Jean-Francois Toussaint, Global Head of Research and Development, Sanofi Pasteur said: “During the COVID-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before. However, key areas of innovation such as thermostability and tolerability improvements will be critical to unlock the applications of mRNA in routine vaccination against a broader set of infectious diseases and across all ages. The Sanofi mRNA vaccines Centre of Excellence aims to lead the field in this next chapter of vaccine innovation.”
Thomas Triomphe, Executive Vice President, Global Head of Sanofi Pasteur said: “This massive new investment clearly puts us in the race to develop next-generation vaccines where mRNA technologies can have greatest impact. While mRNA won’t be the solution for every infectious disease, its translation into routine prevention could have immense impact for many unmet public health needs. It now becomes a critical new technology in our comprehensive vaccines toolbox, one which could help reinvent health protection in the future.”